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Introduction
Duramycin is a small tetracyclic peptide produced by the bacterium Streptoverticillium cinnamoneus [1] . Only 19 amino acids in length duramycin is one of very few identified, relatively, short peptides to have a defined 3-dimensional structure [2] . This structure is stable due to the presence of 3 thioether bridges formed via the unusual amino acids lanthionine and methyllanthionine. Further a covalent linkage be-tween the cysteine at duramycin's N-terminal and an alanine residue produces lysinoalanine [3] . The strength of duramycin's structure is likely to confer its resistance to thermal and proteolytic degradation [2] . The presence of the covalent linkages also results in duramycin's stable binding site which selectively recognises the membrane phos-pholipid phosphatidylethanolamine (PE) through binding to its polar head group [4] . Duramycin binds to PE with high specificity with a binding molar ratio of 1:1 and a dissociation constant in the low nanomolar range [5] . The lantibiotic cinnamycin, which is structurally similar to duramycin, was shown to induce non-specific transbilayer membrane movement of phospholipids in model and cell membranes [6] . It is therefore possible that duramycin self-promotes its own binding to cells by inducing movement of PE molecules from the inner to the outer membrane. PE is an abundant membrane phospholipid which is ubiquitous in eukaryotic cells. In quiescent cells PE is predominantly located on the inner cell membrane along with phosphatidylserine [7, 8] . The asymmetrical distribution of PE and phosphatidylserine is enzymatically maintained by a number of ATP-dependent aminophospholipid translocases and floppases and ATP-independent scramblases [9, 10] . On activation PE can become exposed on the outer cell membrane during a number of physiologically important processes such as apoptotic and necrotic cell death, reorganisation of the membrane during cytokinesis and initiation of the coagulation cascade [11] [12] [13] [14] . Upregulation of cell surface PE expression has been observed in cancer cells, cancer de-rived microparticles and on the tumour endothelium of a variety of in vitro and in vivo tumours [1, [15] [16] [17] . It is well documented that upregulation of cell surface exposure of phosphatidylserine occurs after chemotherapy treatment and that this can increase the procoagulant activity of the tumour [18] [19] [20] . On the premise that PE and phosphatidylserine are regulated by the same mechanisms and that both are exposed during apoptosis [21] and after irradiation [1] a number of studies investigated whether PE exposure was upregulated after chemotherapy. It was demonstrated that externalisation of PE, detected by duramycin, could potentially be a marker of early apoptosis and could be utilised as a detection method for the response to chemotherapy treatment [22] [23] [24] .
Photodynamic therapy (PDT) is a minimally invasive treatment that can deliver selective cytotoxic activity towards cancer [25] . PDT requires three essential components; a photosensitising agent, light and oxygen. Accumulation of the photosensitiser (PS) at the site of cancer and activation with light at a specific wavelength causes the PS to transfer energy, via its excited triplet state, to molecular oxygen which is converted from its ground triplet state to an excited singlet state. This leads to the generation of cell damaging reactive oxygen species (ROS) which ultimately causes apoptotic or necrotic cell death [25, 26] . As well as its direct cytotoxic effect on cancer, PDT can have anti-tumour effects via induction of the inflammatory response and damage to tumour vasculature [27, 28] . PDT has been approved for treatment of a variety of cancer types including premalignant and malignant skin cancers [29, 30] , early carcinomas of the oral cavity, pharynx, and larynx [31] , cancers of the GI tract [32] , prostate cancer, bladder cancer, non-small cell lung cancer and brain tumours [25] . PDT has been used as a synergistic method combined with other major therapies e.g. chemotherapy, radiotherapy and surgery [33] [34] [35] as it does not compromise the effect of the therapies and therefore can be used in conjunction without effecting future treatment options for residual or recurrent malignancy [25] . A number of PS have been approved for use in clinical oncology including m-THCP (meta-tetrahydroxyphenylchlorin, Foscan®), ALA (5-aminolevulinic acid, Levulan®) and its methyl ester (Metvix®) and porfimer sodium (Photofrin®). There are a wide range of PS still in pre-clinical and clinical trials [36, 37] .
Porphyrins are highly conjugated heterocyclic tetrapyrroles that were first identified as having photodynamic properties in the 1970s [38, 39] . A porphyrin PS (5-[Aminobutyl-Noxycarbonyl)phenyl]phenyl]-10,15,20-tris(N-methyl-4-pyridinium) porphyrin trichloride) plus light irradiation was able to reduce cell survival and prevent colony forming in prostate epithelial cells at concentrations of N8.75 μM [40] . The porphyrins TTP (5,10,15,20-tetra-p-tolyl porphyrin) and THNP (5,10,15,20-tetra-p-naphthyl-porphyrin) after a light irradiation dose of 4.5 J/cm 2 were able to cause cell death in a human melanoma cell line in a concentration dependent manner [37] . The main disadvantage of PDT is the low selectivity of PS to their target, which can lead to damage to surrounding normal tissue and sustained skin photosensitivity [25] . In an attempt to overcome this research in PDT in oncology has focused on developing PS's conjugated to tumour targeted biological molecules [28] . Porphyrins have been successfully conjugated to a vari-ety of biomolecules including mAbs [26, 41, 42] , lipoproteins [43, 44] and nanoparticles [45] which allowed for more targeted delivery of PS, and therefore a more specific tissue response with limited damage to nor-mal tissue. A number of porphyrins have been developed that conjugate to biomolecules under mild conditions through direct reaction with lysine residues [26, 33, 46] . The two primary amines, cysteine and lysine, at the N-terminal of duramycin offer potential sites for conjugation without interference with duramycin's binding site [3] . Using this theory a number of duramycin conjugates have been developed to take advantage of PE as a possible selective molecular probe. Fluorescent duramycin conjugates have been used to successfully target and image the lymphoma cancer cell line U937 [4] , cancer derived microparticles [17] , prostate tumour endothelium in rats [1] and the endothelium of aortic flow dividers [47] . Duramycin has been radiolabelled with gadolinium [3] and tech-netium-99 m where it was used to image cell death in a rat model of acute myocardial infarction [47] [48] [49] . The radiolabelled duramycin conjugate quickly accumulated in the PE expressing myocardium. Fast accumulation of a duramycin-PS conjugate could potentially provide an advantage over some of the current PS used in the clinical setting as a short drug-light interval could be achieved. Thus patients could receive PDT relatively quickly in the outpatient setting and would have a reduced treatment duration. In this proof of concept study we conjugated duramycin to a porphyrin based PS and assessed its ability to bind to cancer cells via cell surface PE. It has been previously shown that the level of cell surface PE expression, detected by duramycin, was in-creased on the pancreatic cancer cell lines AsPC-1 and CFPAC-1 when apoptotic (induced by campothecin treatment) compared to untreated viable cells and was further increased when the cells were necrotic (induced by 30% H2O2 treatment) [15] . As duramycin can bind to quiescent, apoptotic and necrotic cancer cells it was theorised that a duramycin conjugate could potentially provide targeted treatment of tumours at all stages of progression. We also examined its cytotoxic ac-tivity on ovarian and pancreatic cancer cell lines following irradiation with visible light.
Materials and Methods

Cell Culture
The cancer cell lines AsPC-1 and MIA PaCa-2 were purchased from the American Type Culture Collection (UK). The cancer cell lines A2780 and SK-OV-3 were purchased from the European Collection of Cell Cultures (UK). All cells were grown using distributors' instructions. All cells were cultured in either IMDM, McCoy's 5a Medium Modified or RPMI (Lonza, UK) substituted with 10% FBS (15% for McCoy's 5a Medi-um Modified) (Bio-Sera, UK) and (v/v); 100 units/mL penicillin, 100 μg/mL streptomycin (P/S) (Lonza, UK). All serum was filtered using a 0.2 μM syringe filter prior to addition to media. When not in use all media was stored between 4 and 6 °C. All cells were incubated at 37 °C in a 5% CO2 atmosphere. Cells were cultured in tissue culture flasks (Sarstedt, UK) and removed via scraping when cells were 70-90% confluent. mixed on a rotating shaker at room temperature for 24 h. The crude material was recovered by addition of dichloromethane (5 mL) and filtration through paper. The solid was dissolved in 1 mL of 0.1% aqueous trifluoroacetic acid (TFA) and the 1:1 porphyrin/duramycin conjugate was isolated by semi-preparative HPLC and analysed by electron ionising mass spectrometry (ESI-MS) ( Section 2.3). Recovery of 4.8 mg of conjugate was achieved equating to 34.4% yield. An unconjugated, "capped" porphyrin was used as a control in which the NHS ester group used for conjugation was reacted with butylamine to eliminate any non-specific conjugation [40] . All photosensitiser containing compounds were kept, protected from light, at −20 °C. Final concentrations of the re-suspended lyophilised powder of the conjugate and "capped" control were determined using UV-visible spectrophotometry. ) were re-suspended in 25 μL PBS and added to a 5 mL polypropylene tube (Sarstedt, UK). Duramycin-porphyrin conjugate (5 μL) at required concentration was added to the tubes and incubated at room temperature in the dark for 30 min. Cells were washed with PBS, centrifuged at 320g for 3 min and re-suspended in 300 μL PBS and then analysed using a BD FACScalibur (BD Biosciences, UK).
Flow Cytometric Analysis of Forward Scatter and Side Scatter
Analysis of forward scatter (FSC) and side scatter (SSC) data was performed using BD CellQuest Pro software™ version 5.1 (BD Biosciences, UK) after cells were processed using the method described above. FSC and SSC data using the unconjugated duramycin was collected as part of a study to determine the effect of duramycin on cell viability over a 2 hour time course (unpublished data). These cells were processed using a flow cytometric cell viability analysis method de-scribed previously [16] . Briefly cells (2 × 10 5 ) were incubated with an appropriate concentration of unconjugated duramycin at room temperature in the dark for 30 min and analysed using Annexin V: FITC Apoptosis Detection Kit I (BD Biosciences, UK).
Competition Binding Assays
Cells (2 × 10 5 ) were re-suspended in 40 μL PBS and added to a 5 mL polypropylene tube (Sarstedt, UK). Duramycin-porphyrin conjugate (10 μL, final concentration 50 μM) was added to the tubes and incubated at room temperature in the dark for 5 min. The cells were washed with PBS, centrifuged at 320g for 3 min and re-suspended in 40 μL PBS except for the 0 minute tube which was resuspended with 300 μL PBS and analysed by flow cytometry. Unconjugated duramycin (10 μL, final con-centration 50 μM) was added to the remaining tubes. After appropriate incubation time (2, 5, 15 or 30 min) 250 μL PBS was added to the tubes and the cells analysed using flow cytometry.
Photodynamic Light Treatment Cells
Cells (8 × 10 5 ) in serum free medium were added to 5 mL polypro-pylene tubes (Sarstedt, UK) containing duramycin-porphyrin conjugate at required concentration (0-10 μM) and incubated in the dark at 37 °C in a 5% CO2 atmosphere for 5 min. Cells were then washed with 3 mL medium so as to remove any unbound conjugate and centrifuged at 300g for 10 min and re-suspended in 1 mL medium. Cells (8 × 10 4 ) were then plated into 96 well plates and incubated in the dark at 37 °C in a 5% CO2 atmosphere for 5 min. The PDT light supply (9 × 14 LED Array, wavelength 620-660 nm) was allowed to stabilise and irradiance reading taken using a R203 Macam radiometer (Irradian Ltd. UK). After incubation one plate was irradiated with a light fluence of 7.5 J/cm 2 red light whilst the other served as the dark control (i.e. not irradiated). After light treatment 5 μL FBS was added to each well and the plates incubated at 37 °C in a 5% CO2 atmosphere for 24 h.
Cell Proliferation Assay
After 24 h incubation 10 μL MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide; thiazolyl blue) (Sigma-Aldrich, UK) (12 mM solution in PBS) was added to each well of the 96 well plates. The plates were incubated at 37 °C in a 5% CO2 atmosphere for 4 h and then the crystals were dissolved by adding 150 μL of acid-alcohol mix-ture (0.04 mol/L HCl in absolute 2-propanol). The plates were then analysed at 570 nm using a Biotek ELX800 Universal Microplate Reader (Corgenix Ltd., UK). Percentage cell survival was expressed relative to control values.
Statistical Analysis
Statistical difference between the irradiated and non-irradiated conjugate conditions and between the duramycin-porphyrin conjugate and unconjugated duramycin conditions was performed using the t-test for unequal variances (heteroscedastic) and a p value of b0.05 was considered statistically significant.
Results
Phosphatidylethanolamine Detection
The duramycin-porphyrin conjugate ( Fig. 1 ) was able to detect cell surface PE expression on the ovarian cancer cell lines, A2780 and SK-OV-3, and the pancreatic cancer cell lines, AsPC-1 and MIA PaCa-2 using flow cytometry. Log10 median PE fluorescence (635 nm laser, FL-4 flow cytometer channel) was used to express levels of detected PE. The duramycin-porphyrin conjugate detected levels of PE in a con-centration dependent manner on all 4 cell lines (n = 2) ( Fig. 2) . Optimal PE detection was seen using the highest concentration (1 mM) of the conjugate. As an average of all 4 cell lines the log10 median PE fluorescence increased from 0.17 ± 0.007 (n = 8) when detected with 1 μM conjugate to 2.21 ± 0.192 (n = 8) when detected with 1 mM conjugate. The duramycin-porphyrin conjugate was detectable through the flow cytometer's FL-4 channel (flow cytometer's 635 nm laser) due to fluorescence of the porphyrin component of the conjugate at this wavelength. 
Competitive Binding for Phosphatidylethanolamine
To investigate whether the binding ability of the duramycin-porphyrin conjugate to PE was affected by the conjugation procedure a competition assay was performed using flow cytometry. The unconjugated duramycin was unable to compete for cell surface PE on the cancer cell lines which had been pre-incubated with duramycin-porphyrin conjugate ( Fig. 3) . The median PE fluorescence (FL-4 channel) of A2780 and MIA PaCa-2 was determined, using the pre-bound conjugate, as 10.9 ± 0.75 (n = 2) and 16.7 ± 5.9 (n = 2), respectively. Duramycin was incubated with the cancer cell lines for 0, 2, 5, 15 and 30 min to allow time to potentially displace the conjugate and competitively bind to PE. The median PE fluorescence of MIA PaCa-2 remained con-stant, within standard deviation, at each interval across the 30 minute time course. The median PE fluorescence of the A2780 however increased over time to the maximum of 12.8 ± 0.16 (n = 2) at 30 min. The unaffected binding affinity of the conjugate for PE after ligation to porphyrin provides evidence that the conjugation method used in this study does not disrupt PE binding. Alternatively, the assay was per-formed with the unconjugated duramycin pre-bound and the conjugate as the competing species, similarly over a 30 min time course. The median PE fluorescence (FL-1 channel) detected remained constant at 8.3 ± 1.8 (n = 2) for A2780 and 11.7 ± 1.4 (n = 2) for MIA PaCa-2 over the 30 min. However it cannot be certain that the FL-1 signal originated from the unconjugated duramycin (labelled with a tertiary FITC antibody detected at 488 nm) as the duramycin-porphyrin conjugate signal is also detectable on this channel. 
Effect on Cell Size and Morphology
We have previously reported the effect that unconjugated duramycin has on the morphology of A2780, AsPC-1, MIA PaCa-2 and SK-OV-3 with relation to an increase in cell size (FSC) and internal cell complexity/granularity (SSC) [16] . FSC and SSC data collected via flow cytometry was analysed after the same 4 cancer cell lines were treated with the duramycin-porphyrin conjugate at concentrations between 1 μM and 1 mM ( Fig. 4) . A2780 and SK-OV-3 increased in SSC when treated with 1 mM conjugate and AsPC-1 and MIA PaCa-2 increased in SSC when treated with N250 μM (n = 2). A2780 and MIA PaCa-2 showed a slight increase in FSC when treated with 1 mM duramycin-porphyrin conjugate (n = 2). 
Photodynamic Cytotoxicity Assays
The duramycin-porphyrin conjugate was used in the photodynamic treatment of the cancer cell lines A2780, AsPC-1, MIA PaCa-2 and SK-OV-3. Each concentration of either "capped" control porphyrin, unconjugated duramycin or duramycin-porphyrin conjugate was repeated 4 times as biological replicates and each assay performed 3 times as tech-nical replicates. The irradiated duramycinporphyrin conjugate was able to reduce the cell survival of the A2780 cancer cells at concentrations ≥5 μM ( Fig. 5a) . A significant difference (p = 0.029) in reduction in cell survival between the irradiated and non-irradiated conjugate treated cells occurred at 5 μM where cell survival was 17.7 ± 26.9% and 65.9 ± 2.4%, respectively. The conjugate at the highest concentration of 10 μM was able to reduce cell survival to 3.2 ± 3.7%. The unconjugated duramycin caused a slight reduction in cell survival at concentrations N5 μM. The non-irradiated "capped" control porphyrin (porphyrin with no duramycin) showed no cytotoxicity. The irradiated "capped" control porphyrin however showed similar levels of cytotoxic-ity as the irradiated conjugate treated cells at concentrations N5 μM. MIA PaCa-2 cells showed similar sensitivity to photodynamic light treatment as A2780. For conjugate treated MIA PaCa-2 cells the differ-ence in reduction of cell survival between the irradiated and non-irradi-ated conditions also occurred at 5 μM ( Fig. 5b ) though this was not significantly different (p = 0.32). At 10 μM cell survival was reduced to 36.3 ± 13.4%. At a concentration of 10 μM the cell survival for the irradiated and non-irradiated unconjugated duramycin was 40.3 ± 16.3% and 43.5 ± 14%, respectively. The non-irradiated conjugate and "capped" control porphyrin showed no cytotoxicity. The irradiated "capped" control porphyrin reduced cell survival slightly at the highest concentration of 10 μM. The cancer cell lines AsPC-1 ( Fig. 5c ) and SK-OV-3 ( Fig. 5d) were more sensitive to photodynamic light treatment than A2780 and MIA PaCa-2. The significant reduction in cell survival between the irradiated and non-irradiated conjugate occurred at 2.5 μM (p = 0.018) for AsPC-1. The cell survival of non-irradiated AsPC-1 cells treated with 2.5 μM conjugate was 86.4 ± 4.9% compared to irradiated cells at 6.3 ± 2.4%. For SK-OV-3 cells the significant reduction in cell survival occurred at 0.5 μM (p = 0.039) and was 95.5 ± 3.9% and 86.9 ± 3.8% for the non-irradiated and irradiated conditions, respectively. This reduction in cell survival became more pronounced at 2.5 μM where cell survival for non-irradiated conjugate treated cells was 91.2 ± 7.7% and only 11.7 ± 4.4% for irradiated cells. At the highest concentration of 10 μM duramycin-porphyrin conjugate reduced cell survival to 1.83 ± 1% in AsPC-1 and 2.76 ± 2.2% in SK-OV-3. The non-ir-radiated conjugate showed dark toxicity at concentrations N5 μM and he irradiated "capped" control porphyrin control slightly reduced cell survival at 10 μM for both cancer cell lines. Unconjugated duramycin showed a cytotoxic effect in a concentration dependent manner for both AsPC-1 and SK-OV-3. For example at 10 μM the irradiated unconjugated duramycin reduced cell survival to 48.7 ± 20.2% in AsPC-1 and 60.6 ± 7.2% in SK-OV-3. Indeed unconjugated duramycin reduced cell survival in a concentration dependent manner in all 4 cell lines. However this is to be expected due to the cytotoxic abilities of unconjugated duramycin at these concentrations as seen previously [16] . Yet, a significantly enhanced cytotoxic effect of the irradiated duramycin-porphyrin conjugate over unconjugated duramycin occurred at concentrations N1. 25 
Discussion
Conjugation of tetrapyrroles to peptides can be chemically challenging due to the requirement of bringing the two moieties together regioselectively whilst maintaining their separate functionalities [33] . In this study conjugation occurred by the formation of a covalent amide bond between an Nhydroxysuccinimide (NHS) ester of the porphyrin and the ε-amino group on the lysine residue at duramycin's N-terminal. The reaction conditions were chosen in order to target the desired lysine residue. NHS esters are highly amine-reactive and form stable amide bonds primarily with lysine's ε-amino group and the α-amino group of the N-terminal residue under physiological or slightly alkaline pH (pH 7.2-9) [51] . As the NHS ester was non-sulphonated, causing it to be water insoluble, the reaction was performed in the water miscible organic solvent DMSO. To produce a pH of pH 9, provide a base in the non-aqueous DMSO solution and catalyse the reaction be-tween NHS and lysine trimethylamine (TEA) was added [50] . In addition to the reaction conditions used the structure of duramycin means it is reasonable to presume the desired location for conjugation was achieved. The only exposed reactive functionality on duramycin is the ε-amino group of the N-terminal lysine residue as the α-amino group of the lysine and the amino terminus itself is folded inside the peptide's structure. The conjugation of the porphyrin to duramycin at this chosen location should minimise interference with the PE binding site [3] . A number of biological molecules conjugated to porphyrin through lysine residues have been shown to retain their antimicrobial function [50, 52, 53] . The scFv antibody fragment LAG-3 when conjugated through its ly-sine residues to a porphyrin PS was shown to bind to the colorectal cancer cell line Caco-2 and effectively induce cell death following 15 J/cm 2 light treatment [26] .
In this study the duramycin-porphyrin conjugate was used to detect cell surface PE expression on the 4 cancer cell lines A2780, AsPC-1, MIA PaCa-2 and SK-OV-3 via flow cytometry. In this way the conjugate was tested to see whether the duramycin component's ability to bind the ethanolamine head group of PE had been altered during conjugation. It was also assessed herein whether the porphyrin had retained its fluorescent properties. The conjugate detected PE expression on all 4 cell lines and was detected in a concentration dependent manner thus verifying the conjugates ability to bind its target and maintain detectable fluorescence. Though it was not shown directly in this study that there was an upregulation of PE on the cancer cell lines compared to their nor-mal counterparts, we have previously shown that PE expression occurs on a broad range of cancer cell lines [16] . Also it has been recently shown that PE was present in much higher abundance in xenografts formed from a number of different tumour types (lung, colon, pancreatic and glioblastoma) than in their normal tissue counterparts [54] . It is well established that duramycin binds to PE when exposed on the sur-face of cells and on the luminal surface of the endothelium [1, 15, 47, 49, 55] . Duramycin was used in conjunction with bavituximab to image the co-localisation of exposed PE and phosphatidylserine on irradiated endothelial cells [56] . The cells were stained 24 hour post irradiation and coincidental exposure of the two phospholipids was observed on the surface of the cells. Duramycin staining occurred only where PE was exposed on the surface of the cell, even when the exposure area moved due to cell movement across the dish, and this staining was maintained on the surface over the 8 hour imaging period. Therefore we theorise that the binding of duramycin and thus the duramycin-porphyrin conjugate occurs only at the cell surface where PE is exposed and is likely not internalised. To further investigate whether the conjugate's PE binding ability was affected by the conjugation procedure a competition assay was performed via flow cytometry. Unconjugated duramycin did not have the ability to outcompete the conjugate for binding of cell surface PE. The median PE fluorescence detected remained constant for MIA PaCa-2 cells over the 30 minute time course and was seen to slightly increase for A2780.
We have previously reported that unconjugated duramycin has an effect on the FSC and SSC properties of cancer cell lines [16] . Duramycin has the ability to increase cell size (FSC) of AsPC-1 and SK-OV-3 cells at N50 μM and increase cell granularity (SSC) of A2780, AsPC-1, MIA PaCa-2 and SK-OV-3 at N200 μM. Necrotic cell death is associated with swelling of the cell followed by rapid release of intracellular content and an increase in granularity which have been linked to an increase in FSC and SSC, respectively [57] . An increase in SSC was seen to correlate with increased granularity in prostate cancer cells (LNCaP and PC3) [58] . Cells with an increased SSC in the renal proximal tubular epithelial cell line LLC-PK1 were identified as apoptotic by flow cytometry and those with an increased FSC as necrotic [59] . Heightened SSC was also seen in early apoptotic cells where condensation of the cell nucleus and cytoplasm during cell shrinkage lead to enhanced light refraction [60] . However it is important to state that morphological and cell size changes measured via light scatter should be considered as supportive rather than as definitive evidence of cell death. We have previously shown via confocal imaging that duramycin treated AsPC-1 cells lose cell membrane staining accompanied with an uptake of propidium iodide suggesting a loss in membrane integrity or cell death. An increase in cell size was also observed, which is indicative of cell swelling prior to cell death [16] . The duramycin-porphyrin conjugate also effected the FSC/SSC properties of the ovarian and pancreatic cancer cell lines. FSC was increased in A2780 and MIA PaCa-2 when treated with 1 mM conjugate and SSC increased in all 4 cell lines though AsPC-1 and MIA PaCa-2 at N250 μM and A2780 and SK-OV-3 at 1 mM. The similar effects on FSC and SSC produced by duramycin and duramycin-porphyrin conjugate could provide additional evidence of duramycin's maintained functionality when conjugated to porphyrin. The higher concentration of conjugate required to exert this effect on the cell lines compared to duramycin alone is beneficial to PDT where minimal non-specific dam-age is a desired characteristic of any PS [36] .
A number of studies in the literature have investigated the effect of PDT on ovarian and pancreatic cancer in a variety of models including cell lines [61] , 3D cell culture [62] [63] [64] , transplanted mice [65, 66] and Phase I/II human trials [67, 68] . A benzoporphyrin derivative (BPD) at 0.25 μM was able to reduce cell viability and volume in the human ovarian carcinoma cell line OVCAR5 and penetrate well through OVCAR5 3D cell culture [62, 63] . In another study in which OVCAR5 cells were grown in a culture film a fibre optic delivery system was used where the PS (pheophorbide) and oxygen gas was delivered separately [64] . Good diffusion of the PS to cells beyond the reach of the probe tip was observed. Balb/C mice transplanted with the ovarian cancer cell line OVCAR3 where treated with an immunoconjugated PS and irradiated with in vivo results showing targeted treatment and minimal damage to the surrounding vasculature [65] . A pancreatic cell line panel showed the cancer cell line AsPC-1 was particularly sensitive to PDT. Treatment of this cell line with verteporfin at 250 nM with a light dose of 10 J/cm 2 was effective enough to induce complete cell death [61] . Verteporfin has been used successfully in a Phase I/II trial against advanced pancreatic cancer where it accumulated quickly in the target tissue, induced necrotic cell death and had a fast clearance via excretion in bile [68] .
In this study we used 2 ovarian and 2 pancreatic cancer cell lines to evaluate the cytotoxic extent of our newly developed PS, duramycin-porphyrin conjugate, taking advantage of duramycin's specificity for cell surface expressed PE. The duramycin-porphyrin conjugate was able to reduce cell survival of all 4 cancer cell lines after irradiation with a light dose of 7.5 J/cm 2 red light. The difference in cell survival be-tween the non-irradiated and irradiated cells treated with the conjugate occurred at 0.05 μM for SK-OV-3, 2.5 μM for AsPC-1 and 5 μM for A2780 and MIA PaCa-2 (though not statistically significant for MIA PaCa-2). Treatment with 10 μM conjugate was effective enough to reduce cell survival to b6% in A2780, AsPC-1 and SK-OV-3. MIA PaCa-2 exhibited less sensitivity to the PDT light treatment as cell survival was only ever reduced to 36.3% at the highest concentration. Reduction in cell survival of MIA PaCa-2 in conjugate treated cells was not significantly different to unconjugated duramycin treated cells. The greater resistance to irradiation and the lack of increased cytotoxic effect of the conjugate over duramycin alone may suggest that MIA PaCa-2 cancer cells may not be a candidate for PDT using this PS. Out of the 2 pancreatic cancer cell lines used in this study MIA PaCa-2 is the less aggressive form. Samkoe et al. [66] discovered that aggressive, fast growing pancreatic cancer (AsPC-1) responded better to verteporfin PDT than the less aggressive cell line (PANC-1) in transplanted mice. In their vascular occlusion experiments 40 J/cm light dose was enough to induce com-plete necrosis in the tumours of AsPC-1 transplanted mice but not in PANC-1. They concluded that this difference in reaction to light treament between cell lines could depend on tumour aggressiveness and other inherent biophysical properties. It has been observed in human trials that these differences in response to light treatment are of clinical importance where light dose can raise different reactions even in patients with the same type of malignancy [28, 67] .
The "capped" porphyrin control when irradiated reduced cell survival slightly in AsPC-1, SK-OV-3 and MIA PaCa-2 at 10 μM. In a recent study [40] this "capped" control porphyrin was used in PDT experiments against benign and malignant prostate cells to assess its cytotoxic potential. "Capped" porphyrin N8.75 μM was seen to induce necrosis and prevent colony forming in irradiated prostate cells. In the A2780 cancer cell line the capped porphyrin control produced similar levels of cytotoxicity as to that produced by the irradiated conjugate. An increased uptake and localisation of the "capped" porphyrin could potentially explain this increased sensitivity. However DNA damage in the prostate cells (suggesting localisation occurred in the nucleus) was induced after 1 hour incubation with the porphyrin [40] . This movement into the cell and localisation of the "capped" control porphyrin is unlike-ly to have occurred in the A2780 cells in the relatively short incubation of 5 min used in this study.
The differences in sensitivities to irradiation between cancer cell lines could potentially be explained by the cytoprotective mechanisms that cancer cells can employ to escape PDT induced cell death. Antioxidant molecules and detoxifying enzymes such as superoxide dismutase (SOD) present in cancer cells have been implicated in the protection against PDT effects [25] . Other cytoprotective mechanisms have been demonstrated to be induced by PDT itself including the i) initiation of stress-related transcription factors e.g. hypoxia inducible factor (HIF) and nuclear factor erythroid 2-related factor 2 (NRF2), ii) increased heat shock protein (HSP) levels e.g. elevated HSP60 and HSP70 have been seen to be inversely correlated with PDT sensitivity and iii) inhibition of NF-ᴋB which can activate anti-apoptotic genes [25] . The literature reports at least some of these protective mechanisms are active in the ovarian and pancreatic cancer cell lines used in this study. An upregulation of HIF-1-α, an important factor in tumour metastasis and progression, was seen to accompany the hypoxic state of A2780 tumours and has also been observed in hypoxia induced MIA PaCa-2 cells and following oxidative stress-induced ROS production in SK-OV-3 cells [71] . SK-OV-3 cells also have an upregulation of the antioxidant gene SOD2 [72] which could protect against harmful PDT effects. This ovarian cancer cell line has also been shown to have enhanced NF-ᴋB activity, when stimulated by ROS, which lead to the activation of anti-apoptotic genes [73] . NRF2 is the principal transcription factor of many antioxidant and detoxification genes and is overexpressed in A2780 [74] , SK-OV-3 [75] and AsPC-1 cells [76, 77] and can be induced in the presence of ROS especially in pancreatic cancer [77] . HSPs can bind oxidatively damaged proteins and play a role in pro-survival path-ways [25] . HSP70 is overexpressed in MIA PaCa-2 cells [78] and is found in much higher quantities in tissue from patients with ovarian cancer than in normal ovarian tissue [79] . The effectiveness of PDT relies on an available and sustained oxygen supply to tissue, which may be reduced in hypoxic conditions [80] . A2780 xenografts in a murine model of ovarian cancer were found to be extremely hypoxic (2.0 ± 0.7 mmHg) when compared to RIF-1 xenografts (7.8 ± 1.4 mmHg); a typical hypoxic tumour model [69] . An important property of any good PS is a high intersystem crossing (ISC) yield i.e. a high possibility of conversion from the excited singlet state to the longer lived excited triplet state, from which energy transfer to ground state (triplet) oxygen occurs [28] . Tetrapyrroles, such as the porphyrin moiety used in this study, are very efficient at undergoing ISC [81] . The benefit of conjugating tetrapyrroles with peptides is that their small size allows for good tissue penetration and usually renders them non-immunogenic [33] . An advantage of the type of porphyrin used in this study is that the conjugation procedure does not produce reactive intermediates or by-products [26, 46] . This porphyrin has previously been shown to exhibit antibacterial properties, be an efficient cytotoxic after 5 minute irradiation and be stable against photodegradation [50] . The duramycin-porphyrin conjugate reported here is an effective PS for the targeted PDT treatment of cancer cells. With a relatively low (in vitro) cytotoxic concentration of ≥0.5 μM (de-pendent on cell line) the conjugate offers benefits over unconjugated duramycin induced cell death. At these low concentrations duramycin does not cause necrosis but can reliably bind cell surface expressed PE Unconjugated duramycin has been shown to bind PE expressed on the tumour vasculature [1] . Through the possibility of targeted irradiance the duramycin-porphyrin conjugate could allow for specific death of the tumour and therefore reduce the risk of collateral damage to surrounding normal tissue. Photodynamic effect usually occurs very close to the localisation of the PS [25] and when the PS's binding site is the plasma membrane necrotic cell death can very rapidly follow irradiation [82] . As the duramycin-porphyrin conjugate binds to cancer cell membranes it is possible that cell death occurs via rapid necrosis which may reduce the risk of PDT-induced cytoprotective mechanisms. PDT is evidently an effective anti-cancer therapy though only a limited number of PS have been approved by the FDA and EU for use in the clinical setting [28, 37] . For PDT to be better utilised as a treatment strategy the development of PS that possess selectivity for binding sites overexpressed or enhanced on a wide range of cancer types is needed. In this proof of concept study we have shown that the PS duramycin-porphyrin conjugate retained good binding affinity for its target and, following irradiation, reduced cell survival of pancreatic and ovarian cancer cell lines in a concentration dependent manner. As we have previously shown, duramycin has the ability to bind to cell surface expressed PE on a range of cancer cell lines [16] , and so we hypothesise that this PS could potentially be used against a number of different cancer types. Further work with duramycin-porphyrin conjugate in the in vivo environment could potentially confirm this conjugate as a promising new PS in the PDT treatment of cancer.
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